BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BMRN shares.
View BMRN analyst ratings or view top-rated stocks.

14 Wall Street research analysts have issued 12-month price targets for BioMarin Pharmaceutical's stock. Their BMRN share price forecasts range from $74.00 to $135.00. On average, they anticipate the company's stock price to reach $113.43 in the next year. This suggests a possible upside of 33.8% from the stock's current price.
View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts.

BioMarin Pharmaceutical's stock was trading at $88.35 at the beginning of the year. Since then, BMRN shares have decreased by 4.1% and is now trading at $84.77.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our BMRN earnings forecast.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its earnings results on Wednesday, August, 3rd. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.13. The biotechnology company earned $533.80 million during the quarter, compared to analyst estimates of $514.18 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 1.78% and a net margin of 2.83%. During the same period in the previous year, the business earned $0.23 EPS.

BioMarin Pharmaceutical updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.06 billion-$2.16 billion, compared to the consensus revenue estimate of $2.11 billion.

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BMRN stock can currently be purchased for approximately $84.77.

BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $15.72 billion and generates $1.85 billion in revenue each year. The biotechnology company earns $-64,080,000.00 in net income (profit) each year or $0.26 on an earnings per share basis.

The company employs 3,045 workers across the globe.

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889.